Work

Abstract A23: Type II JAK2 inhibitor NVP-CHZ868 has potent activity in JAK2-dependent B-cell acute lymphoblastic leukemias (B-ALLs) in vivo.

Year: 2015

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.hemmal14-a23

Authors: Loretta S. Li, Nadja Kopp, Shuo-Chieh Wu, Jordy Van Der Zwet, Jacob V. Layer, Oliver Weigert, Amanda L. Christie, Alexandra N. Christodoulou, Huiyun Liu, Akinori Yoda, Thomas Radimerski, David M. Weinstock

Institutions: Dana-Farber Cancer Institute, Ludwig-Maximilians-Universität München, Novartis Institutes for BioMedical Research

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2417876721

Cites:

Cited by:

Related to: 10